Janux Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 64
- Market Cap
- $2.3B
- Website
- http://www.januxrx.com
- Introduction
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckColorectal CarcinomaSmall Cell Lung CancerPancreatic Ductal AdenocarcinomaTriple-negative Breast Cancer
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Janux Therapeutics
- Target Recruit Count
- 130
- Registration Number
- NCT05783622
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of California San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate CancerCastration Resistant Prostatic Cancer
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Janux Therapeutics
- Target Recruit Count
- 272
- Registration Number
- NCT05519449
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸UCLA Department of Medicine, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
News
Janux Therapeutics Receives $10 Million Milestone Payment from Merck as First Patient Dosed in TRACTr Cancer Immunotherapy Trial
Janux Therapeutics received a $10 million milestone payment from Merck following the dosing of the first patient in their TRACTr collaboration for cancer immunotherapy development.
Janux Therapeutics Advances Multi-Platform Pipeline with Novel ARM Technology for Autoimmune Diseases
Janux Therapeutics showcased its expanded immunotherapy pipeline at R&D Day, highlighting three proprietary platforms: TRACTr, TRACIr, and the novel ARM platform targeting autoimmune diseases.
Advanced Renal Cell Carcinoma Pipeline Shows Strong Growth with 60+ Therapies in Development
DelveInsight's assessment reveals over 50 companies are actively developing 60+ advanced renal cell carcinoma therapies across various clinical phases.
Janux Therapeutics Advances JANX007 to Phase 1b Trials for Prostate Cancer with Promising Survival Data
Janux Therapeutics has initiated Phase 1b expansion studies of JANX007 in taxane-naïve metastatic castration-resistant prostate cancer patients, marking progression to earlier treatment lines.
Janux Data Boosts Confidence in Vir Biotechnology's Masked TCE Pipeline
• Morgan Stanley highlights Janux Therapeutics' positive Phase 1a data for JANX007 in metastatic castration-resistant prostate cancer. • The analyst suggests these findings provide a favorable readthrough for Vir Biotechnology's masked T-cell engager (TCE) pipeline. • Vir Biotechnology is anticipated to release initial Phase 1 monotherapy data from VIR-5818 and VIR-5500 in the first quarter of 2025. • Morgan Stanley maintains an Equal Weight rating on Vir shares, setting a price target of $10.
Janux Therapeutics' JANX007 Shows Promise in Advanced Prostate Cancer Trial
Janux Therapeutics' JANX007 demonstrated significant PSA reduction in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Janux Therapeutics' JANX007 Shows Promising Activity in Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics' JANX007 demonstrated substantial clinical activity in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients.